Toll-like receptor 4 gene polymorphisms show no association with the risk of clinical or angiographic restenosis after percutaneous coronary intervention

Pharmacogenetics and Genomics

Volumn 20, Issue 9, 2010, Pages 544-552

  Beijk, Marcel A M ^a   Boekholdt, S Matthijs ^a   Rittersma, Saskia Z H ^a   Pons, Douwe ^b,c,d   Zwinderman, Aeilko H ^a   Doevendans, Pieter A F ^e   Tio, Rene A ^f   Tijssen, Jan G P ^a   Jukema, J Wouter ^a,b,c   De Winter, Robbert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b Durrer Center for Cardiogenetic Research   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

^e UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

genetics; percutaneous coronary intervention; restenosis; TLR4 polymorphisms

Indexed keywords

ASPARTIC ACID; GLYCINE; ISOLEUCINE; THREONINE; TOLL LIKE RECEPTOR 4;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; DNA POLYMORPHISM; DRUG ELUTING STENT; FEMALE; GENE LOCUS; GENETIC RISK; GENOTYPE; HAPLOTYPE; HUMAN; INNATE IMMUNITY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; RISK ASSESSMENT;

EID: 77955919206     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32833d7b29     Document Type: Article

References (34)

1. Serruys PW, Kutryk MJ, Ong AT. Coronary-artery stents. N Engl J Med 2006; 354:483-495.
2. Colombo A, Sangiorgi G. The monocyte: the key in the lock to reduce stent hyperplasia? J Am Coll Cardiol 2004; 43:24-26.
3. Welt FG, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22:1769-1776.
4. Farb A, Sangiorgi G, Carter AJ, Walley VM, Edwards WD, Schwartz RS, et al. Pathology of acute and chronic coronary stenting in humans. Circulation 1999; 99:44-52.
5. Farb A, Weber DK, Kolodgie FD, Burke AP, Virmani R. Morphological predictors of restenosis after coronary stenting in humans. Circulation 2002; 105:2974-2980.
6. Komatsu R, Ueda M, Naruko T, Kojima A, Becker AE. Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses. Circulation 1998; 98:224-233.
7. Bidwell J, Keen L, Gallagher G, Kimberly R, Huizinga T, McDermott MF, et al. Cytokine gene polymorphism in human disease: on-line databases, supplement 1. Genes Immun 2001; 2:61-70.
8. Verschuur M, van der Beek MT, Tak HS, Visser LG, De Maat MP. Interindividual variation in the response by fibrinogen, C-reactive protein and interleukin-6 to yellow fever vaccination. Blood Coagul Fibrinolysis 2004; 15:399-404.
9. Warle MC, Farhan A, Metselaar HJ, Hop WC, Perrey C, Zondervan PE, et al. Are cytokine gene polymorphisms related to in vitro cytokine production profiles? Liver Transpl 2003; 9:170-181.
10. Horibe H, Yamada Y, Ichihara S, Watarai M, Yanase M, Takemoto K, et al. Genetic risk for restenosis after coronary balloon angioplasty. Atherosclerosis 2004; 174:181-187.
11. Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, De Maat MP, et al. Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 2005; 112:2417-2425.
12. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2001; 2:675-680.
13. Kopp EB, Medzhitov R. The Toll-receptor family and control of innate immunity. Curr Opin Immunol 1999; 11:13-18.
14. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997; 388:394-397.
15. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F. Toll-like receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol Chem 1999; 274:10689-10692.
16. Okamura Y, Watari M, Jerud ES, Young DW, Ishizaka ST, Rose J, et al. The extra domain A of fibronectin activates Toll-like receptor 4. J Biol Chem 2001; 276:10229-10233.
17. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor-4 complex. J Immunol 2000; 164:558-561.
18. Yao EH, Fukuda N, Ueno T, Matsuda H, Nagase H, Matsumoto Y, et al. A pyrrole-imidazole polyamide targeting transforming growth factor-beta1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc Res 2009; 81:797-804.
19. Zarember KA, Godowski PJ. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J Immunol 2002; 168:554-561.
20. Edfeldt K, Swedenborg J, Hansson GK, Yan ZQ. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002; 105:1158-1161.
21. Vink A, Schoneveld AH, van der Meer JJ, Van Middelaar BJ, Sluijter JP, Smeets MB, et al. In vivo evidence for a role of toll-like receptor 4 in the development of intimal lesions. Circulation 2002; 106:1985-1990.
22. Hollestelle SC, de Vries MR, Van Keulen JK, Schoneveld AH, Vink A, Strijder CF, et al. Toll-like receptor 4 is involved in outward arterial remodeling. Circulation 2004; 109:393-398.
23. Arbour NC, Lorenz E, Schutte BC, Zabner J, Kline JN, Jones M, et al. TLR4 mutations are associated with endotoxin hyporesponsiveness in humans. Nat Genet 2000; 25:187-191.
24. Agema WR, Monraats PS, Zwinderman AH, de Winter RJ, Tio RA, Doevendans PA, et al. Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 2004; 25:1163-1170.
25. Van der Zwet PM, Reiber JH. A new approach for the quantification of complex lesion morphology: the gradient field transform; basic principles and validation results. J Am Coll Cardiol 1994; 24:216-224.
26. Lorenz E, Frees KL, Schwartz DA. Determination of the TLR4 genotype using allele-specific PCR. Biotechniques 2001; 31:22-24.
27. Barrett JC, Fry B, Maller J, Daly MJ. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21:263-265.
28. Rittersma SZ, Kremer Hovinga JA, Koch KT, Boekholdt SM, van Aken BE, Scheepmaker A, et al. Relationship between in vitro lipopolysaccharide-induced cytokine response in whole blood, angiographic in-stent restenosis, and toll-like receptor 4 gene polymorphisms. Clin Chem 2005; 51:516-521.
29. Kiechl S, Lorenz E, Reindl M, Wiedermann CJ, Oberhollenzer F, Bonora E, et al. Toll-like receptor 4 polymorphisms and atherogenesis. N Engl J Med 2002; 347:185-192.
30. Ameziane N, Beillat T, Verpillat P, Chollet-Martin S, Aumont MC, Seknadji P, et al. Association of the Toll-like receptor 4 gene Asp299Gly polymorphism with acute coronary events. Arterioscler Thromb Vasc Biol 2003; 23:e61-e64.
31. Koch W, Hoppmann P, Pfeufer A, Schomig A, Kastrati A. Toll-like receptor 4 gene polymorphisms and myocardial infarction: no association in a Caucasian population. Eur Heart J 2006; 27:2524-2529.
32. Kolek MJ, Carlquist JF, Muhlestein JB, Whiting BM, Horne BD, Bair TL, et al. Toll-like receptor 4 gene Asp299Gly polymorphism is associated with reductions in vascular inflammation, angiographic coronary artery disease, and clinical diabetes. Am Heart J 2004; 148:1034-1040.
33. Boekholdt SM, Agema WR, Peters RJ, Zwinderman AH, van Der Wall EE, Reitsma PH, et al. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Circulation 2003; 107:2416-2421.
34. Holloway JW, Yang IA, Ye S. Variation in the toll-like receptor 4 gene and susceptibility to myocardial infarction. Pharmacogenet Genomics 2005; 15:15-21.